A professional headshot of Samuel Fehling, a smiling man with red hair, wearing a black suit jacket, white shirt, and black tie. He is positioned on the left side of the frame against a dark background, with large wooden barrels faintly visible behind him.

Samuel C.
Fehling, PhD

Drug Discovery & Development

  • Small-Molecule & Antibody Discovery
  • Target Identification & Validation
  • IND-Enabling Study Support

Pharmacology & Assay Development

  • Pharmacodynamic (PD) Assay Design
  • In Vitro & In Vivo Screening
  • Mechanism of Action (MOA) Studies

Specialized Analytics

  • Antibody Characterization (SPR/Biacore)
  • High-Throughput Screening (Gyrolab)
  • Molecular Diagnostics (PCR Platforms)

About Sam

I am a translational scientist with a PhD in Biomedical Sciences (Cancer Biology) and deep expertise in preclinical pharmacology, target validation, and translational biomarker development across small-molecule and antibody programs. Experienced in collaborating across chemistry, biology, in-life, and clinical / non-clinical teams to support IND-enabling studies.

Work Experience

BioCryst Pharmaceuticals, Inc.

Sr. Research Biologist

• July 2025 – October 2026

Focus: Biologics and Pharmacodynamics

Lead Assay Qualification

Developed and qualified high-sensitivity PD assays (Gyrolab) to quantify therapeutic protein levels in NHP models.

Biologics Characterization

Utilized SPR (Biacore T200) to provide critical binding kinetics and cross-reactivity data for candidate selection.

Regulatory Support

Generated comprehensive analytical data and documentation packages to support IND-enabling studies.

Research Biologist

• December 2022 – July 2025

Focus: High-Throughput Screening and Biomarkers

Cross-Modality Screening

Executed high-throughput in vitro screening for both small-molecule and antibody-based therapeutic pipelines.

Biomarker Evaluation

Characterized therapeutic activity and safety through the analysis of rodent and NHP plasma samples.

BioGX, Inc.

Research & Development Scientist

• February 2020 – December 2022

Focus: Molecular Diagnostics and Validation

Diagnostic Development

Developed and qualified multiple PCR-based molecular diagnostic assays for FDA Emergency Use Authorization (EUA).

Quality & Compliance

Managed IQ/OQ/PQ qualifications and QC risk assessments to ensure manufacturing and regulatory readiness.

University of Alabama at Birmingham

Graduate Research Assistant

• August 2014 – December 2019

Focus: Translational Oncology and Disease Modeling

Cancer Research

Investigated drug resistance mechanisms and identified synergistic therapeutic combinations in cholangiocarcinoma and PDAC models.

Complex Modeling

Utilized Patient-Derived Xenograft (PDX) and in vivo mouse models to evaluate therapeutic efficacy and biomarker response.

Technical Skills

Close-up of a researcher wearing a blue lab coat and light blue nitrile gloves, gently cradling a small white albino mouse in their open palms.

Murine Mouse Models

Experienced with athymic nude & C57BL/6 mice, oral gavage, intraperitoneal (IP) injection and patient-derived xenograft (PDX) models.

Several small stacks of petri dishes with red markings, glass bottles, and purple pipette tip boxes organized on a reflective surface inside a laminar flow hood.

In Vitro / Primary Cell Culture

Utilizing commercially available cell culture lines & developing primary cell culture lines from patient tumors.

Close-up of a hand in a white lab glove holding a strip of eight clear microcentrifuge tubes filled with liquid, set against a blurred blue laboratory background.

Laboratory Techniques

  • ELISA
  • Western Blotting
  • PCR and qPCR
  • Surface Plasmon Resonance (SPR)
  • Antibody Screening
  • Target Validation

Preclinical Research

  • Cell Culture (Immortalized and Primary)
  • Patient-Derived Xenograft (PDX) Models
  • Murine Xenograft Models
  • Pharmacodynamic (PD) Studies

Instrumentation

  • Gyrolab xPlore
  • Biacore T200
  • Bio-Rad CFX96 / 364
  • Thermo Fisher QuantStudio
  • ABI 7500

Scientific Software

  • GraphPad Prism
  • Biacore Evaluation Software
  • Gyrolab Evaluator
  • ImageJ (FIJI)
  • Microsoft 365

Creative Projects

Close-up of a person's fingers holding a Raspberry Pi circuit board, showcasing the USB ports, Ethernet jack, and GPIO pins, with vibrant blue and magenta neon lighting in the background.

Computers & Technology

Self-hosted website infrastructure, Linux systems administration, Docker environments, networking and automation projects demonstrating technical problem-solving outside the laboratory. This website is self-hosted on my personal Raspberry Pi 4.

Flat lay composition of drone racing gear on a light blue surface, including a quadcopter with an attached action camera, a multi-channel radio transmitter, and a black video headset.
Mid-section view of a photographer carrying a backpack and holding a professional camera with a long lens, standing before a dramatic, sunlit mountain landscape with sharp peaks.

Photography & Photo Editing

Photographer with expertise in Adobe Photoshop and Lightroom, adept in mirrorless, smartphone and drone photography with over 110 stock photos sold through Shutterstock & Getty.

Education

University of Alabama at Birmingham (UAB)

Ph.D. in Biomedical Sciences (Cancer Biology)
2014 – 2019

  • Cancer Biology Newsletter Editorial Board
  • Cancer Biology Student Seminar Co-Organizer
  • Graduate Career Awareness and Trends (GCAT) Communications Director

University of Wisconsin – Eau Claire (UWEC)

B.S. in Biochemistry & Molecular Biology
2010 – 2014

  • Biology Club Treasurer
  • Molecular Movement Treasurer

Publications

11 Peer-Reviewed Articles with 420+ Citations

Featured Publications

BET Inhibition Decreases HMGCS2 and Sensitizes Resistant Pancreatic Tumors to Gemcitabine

Aubrey L Miller, Samuel C Fehling, Rebecca B Vance, Dongquan Chen, Eric Josh Brown, M Iqbal Hossain, Eric O Heard, Shaida Andrabi, Hengbin Wang, Eddy S Yang, Donald J Buchsbaum, Robert CAM van Waardenburg, Susan L Bellis, Karina J Yoon.

Cancer Letters. 2024 June 28. (PMID: 38704133)

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

Aubrey L. Miller, Patrick L. Garcia, Samuel C. Fehling, Tracy L. Gamblin, Rebecca B. Vance, Leona N. Council, Dongquan Chen, Eddy S. Yang, Robert CAM van Waardenburg, Karina J. Yoon.

Cancers. 2021 July 11. (PMCID: PMC8303731)

The Combination of BET and PARP Inhibitors is Synergistic in Models of Cholangiocarcinoma

Samuel C. Fehling, Aubrey L. Miller, Patrick L. Garcia, Rebecca B. Vance, Karina J. Yoon.

Cancer Letters. 2019 October 9. (PMCID: PMC7017643)

The BET Inhibitor JQ1 Attenuates Double Strand Break Repair and Sensitizes Models of Pancreatic Ductal Adenocarcinoma to PARP Inhibitors

Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg RCAM, Yang ES, Bradner JE, Yoon KJ.

EBioMedicine. 2019 June. (PMCID: PMC6604668)

FTY720 Enhances the Anti-Tumor Activity of Carboplatin and Tamoxifen in a Patient-Derived Xenograft Model of Ovarian Cancer

Kreitzburg KM, Fehling SC, Landen CN, Gamblin TL, Vance RB, Arend RC, Katre AA, Oliver PG, van Waardenburg RCAM, Alvarez RD, Yoon KJ.

Cancer Letters. 2018 August 15(18): 30527-5. (PMCID: PMC6756795)

MicroRNA-31 is Required for Astrocyte Specification

Meares GP, Rajbhandari R, Gerigk M, Tien CL, Chang C, Fehling SC, Rowse A, Mulhern KC, Nair S, Gray GK, Berbari NF, Bredel M, Benveniste EN, Nozell SE.

Glia. 2018 May, 66(5): 987-998. (PMCID: PMC5851835)

A Comparative Study of All-atom Molecular Dynamics Simulation…

Fehling SC, Strom AM, Lehman BP, Andrews RJ, Bhattacharyya S, Hati S.

American Journal of Undergraduate Research. 2017 June; 14(2): 27-44 (DOI: 10.33697/AJUR.2017.012)

Loss of SOCS3 in Myeloid Cells Prolongs Survival in a Syngeneic Model of Glioma

McFarland BC, Marks MP, Rowse AL, Fehling SC, Gerigk M, Qin H, Benveniste EN.

Oncotarget. 2016 April 12; 7(15): 20621-35. (PMCID: PMC4991480)

Loss of Tumor Suppressive microRNA-31 Enhances TRADD/NF-κB Signaling in Glioblastoma

Rajbhandari R, McFarland BC, Patel A, Gerigk M, Gray GK, Fehling SC, Bredel M, Berbari NF, Kim H, Marks MP, Meares GP, Sinha T, Chuang J, Benveniste EN, Nozell SE.

Oncotarget. 2015 July 10; 6(19): 17805-16. (PMCID: PMC4627347)

Comparison of Intrinsic Dynamics of Cytochrome p450 Proteins Using Normal Mode Analysis

Dorner ME, McMunn RD, Bartholow TG, Calhoon BE, Conlon MR, Dulli JM, Fehling SC, Fisher CR, Hodgson SW, Keenan SW, Kruger AN, Mabin JW, Mazula DL, Monte CA, Olthafer AG, Sexton AE, Soderholm BR, Strom AM, Hati S.

Protein Science. 2015 September; 24(9): 1495-507. (PMCID: PMC4570543)

Probing the Global and Local Dynamics of Aminoacyl-tRNA Synthetases using All-Atom and Coarse-Grained Simulations

Strom AM, Fehling SC, Bhattacharyya S, Hati S.

Journal of Molecular Modeling. 2014 May; 20(5): 2245 (PMCID: PMC4030129)

Contact

LinkedIn • Google Scholar • GitHub • ORCID • ResearchGate

Open to Scientist, Senior Scientist, Principal Scientist and Translational Research opportunities in oncology, immunology and drug discovery.

Open to relocation.

Email: [email protected]

Outside the Lab

I Love Exploring Our National Parks and Road Tripping Across the Country. Full Stories Can Be Found On Our Travel Blog, With Each Mile